Retinal vein occlusion Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug

The total Retinal Vein Occlusion market size in the 7MM was approximately USD 2,297.5 million in 2022 and is projected to increase during the forecast period (2023-2034).

Emerging therapies for retinal vein occlusion, including VABYSMO (faricimab), LUCENTIS (ranibizumab), EYLEA (aflibercept), OZURDEX (dexamethasone intravitreal implant), Tarcocimab tedromer (KSI-301), LYTENAVA (bevacizumab)/ONS-5010, and others, are anticipated to drive growth in the retinal vein occlusion market in the coming years.

DelveInsight has released a new report titled "Retinal Vein Occlusion - Market Insights, Epidemiology, and Market Forecast-2034," offering a comprehensive analysis of retinal vein occlusion, including historical and projected epidemiology, as well as market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Retinal vein occlusion market report @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Retinal vein occlusion Market Report:

*
The Retinal Vein Occlusion (RVO) market in the 7MM was valued at around USD 2.3 billion in 2022 and is projected to expand over the forecast period (2023-2034). In the United States, the market accounted for approximately USD 1.6 billion, with growth expected due to rising awareness and the introduction of new therapies. The EU4 and the UK generated about USD 454 million, while Japan contributed USD 232 million in RVO market revenue.

*
Factors such as an aging population and increased awareness of eye disorders are driving the rising prevalence of RVO. Current treatments, including anti-VEGFs, corticosteroids, and laser therapy, focus on limiting damage but do not restore vision long-term. There is a substantial need for therapies that target the underlying cause, halt disease progression, and potentially reduce reliance on ongoing treatment.

*
EYLEA (aflibercept) remains the leading therapy in the RVO market; however, the introduction of biosimilars and newer drugs like VABYSMO (faricimab), approved in 2023, is expected to reshape the landscape. VABYSMO offers improved dosing regimens and better visual outcomes, helping Roche regain market share. Other emerging therapies, including tarcocimab tedromer (KSI-301) and LYTENAVA (ONS-5010), are in late-stage development and have the potential to transform RVO treatment.

*
The market faces challenges from patent expirations and biosimilar approvals, which may impact the uptake of new therapies. In 2022, the US accounted for roughly 61% of total diagnosed RVO cases in the 7MM, with about 935,343 cases, a figure expected to rise over the forecast period. The EU4 and the UK together reported approximately 408,086 diagnosed cases in 2022, with projections indicating changes through 2034.

*
Recent advancements include FDA 510(k) clearance in January 2025 for AI Optics Inc.'s Sentinel Camera, a portable handheld retinal imaging device suitable for primary care, optometry, retail clinics, and home settings. In December 2024, Regeneron Pharmaceuticals announced that the Phase 3 QUASAR trial for EYLEA HD Registered (aflibercept) 8 mg achieved its primary endpoint for treating macular edema due to RVO, including central, branch, and hemiretinal vein occlusions.

*
Key companies developing new RVO therapies include AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others. Promising therapies in development or currently available include VABYSMO (faricimab), LUCENTIS (ranibizumab), EYLEA (aflibercept), OZURDEX (dexamethasone intravitreal implant), Tarcocimab tedromer (KSI-301), and LYTENAVA (bevacizumab)/ONS-5010.

Retinal vein occlusion Overview

Retinal Vein Occlusion (RVO) is the second most prevalent retinal vascular disorder after diabetic retinopathy, occurring when veins responsible for draining blood from the retina become obstructed. This blockage, often caused by atherosclerosis or blood clots, can lead to sudden vision changes, with severity depending on the location and extent of the occlusion. The obstruction increases capillary pressure, resulting in hemorrhage and fluid leakage, which can cause macular edema near the macula.

Risk factors include systemic conditions such as hypertension, arteriosclerosis, diabetes, hyperlipidemia, stroke, blood hyperviscosity, and thrombophilia. Individuals with end-organ damage face an even higher risk. Eye-related risk factors include ocular hypertension, glaucoma, elevated ocular perfusion pressure, and retinal artery changes.

RVO is categorized based on the site of blockage into central Retinal Vein Occlusion (CRVO) and branch Retinal Vein Occlusion (BRVO). CRVO is further classified into ischemic and non-ischemic types according to perfusion status, while BRVO is divided into major branch RVO (blockage near or at the optic disc) and macular branch RVO (blockage in a macular venule).

The condition is more common in older adults, especially those over 65, with age and systemic vascular diseases being primary risk factors. As the elderly population increases, RVO prevalence is expected to rise. Macular edema is a significant complication that leads to vision loss in both CRVO and BRVO, and various treatments are employed to reduce macular swelling and address intraocular neovascularization.

Retinal vein occlusion Market Outlook

Retinal Vein Occlusion (RVO) is a prevalent retinal vascular disorder and a major cause of vision loss worldwide, ranking second only to diabetic retinopathy among retinal vascular diseases leading to blindness. Currently, there is no treatment that can reverse RVO, and most patients experience lasting changes in vision. The main focus of treatment is to stabilize vision by addressing leaking blood vessels.

Although the blocked retinal veins cannot be reopened, physicians can manage related health conditions that contribute to the disorder. In some cases, vision may partially recover: roughly one-third of patients see some improvement, another third remain stable, and the final third gradually improve over time, sometimes taking a year or more to assess outcomes. In certain instances, the obstruction can cause fluid accumulation in the retina or stimulate the growth of new blood vessels.

Discover how the Retinal vein occlusion market is rising in the coming years @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Retinal Vein Occlusion Marketed Drugs

*
VABYSMO (faricimab): Roche/Chugai Pharmaceutical

*
LUCENTIS (ranibizumab): Roche/Novartis

*
EYLEA (aflibercept): Regeneron Pharmaceutical/Bayer/Santen

*
OZURDEX (dexamethasone intravitreal implant): AbbVie

Retinal vein occlusion Emerging Drugs

*
Tarcocimab tedromer (KSI-301): Kodiak Sciences

*
LYTENAVA (bevacizumab)/ONS-5010: Outlook Therapeutics

Scope of the Retinal vein occlusion Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Retinal vein occlusion Companies: AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others

*
Key Retinal vein occlusion Therapies: VABYSMO (faricimab), LUCENTIS (ranibizumab), EYLEA (aflibercept), OZURDEX (dexamethasone intravitreal implant), Tarcocimab tedromer (KSI-301), LYTENAVA (bevacizumab)/ONS-5010, and others

*
Retinal vein occlusion Therapeutic Assessment: Retinal vein occlusion current marketed and Retinal vein occlusion emerging therapies

*
Retinal vein occlusion Market Dynamics: Retinal vein occlusion market drivers and Retinal vein occlusion market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Retinal vein occlusion Unmet Needs, KOL's views, Analyst's views, Retinal vein occlusion Market Access and Reimbursement

To know what's more in our Retinal vein occlusion report, visit https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Retinal vein occlusion Market Report:

*
Retinal vein occlusion market report covers a descriptive overview and comprehensive insight of the Retinal vein occlusion Epidemiology and Retinal vein occlusion market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Retinal vein occlusion market report provides insights into the current and emerging therapies.

*
The Retinal vein occlusion market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Retinal vein occlusion market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Retinal vein occlusion market.

Got queries? Click here to know more about the Retinal vein occlusion market Landscape https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Retinal vein occlusion Patient Share (%) Overview at a Glance

5. Retinal vein occlusion Market Overview at a Glance

6. Retinal vein occlusion Disease Background and Overview

7. Retinal vein occlusion Epidemiology and Patient Population

8. Country-Specific Patient Population of Retinal vein occlusion

9. Retinal vein occlusion Current Treatment and Medical Practices

10. Unmet Needs

11. Retinal vein occlusion Emerging Therapies

12. Retinal vein occlusion Market Outlook

13. Country-Wise Retinal vein occlusion Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Retinal vein occlusion Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Retinal vein occlusion Market Outlook 2034 https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Related Reports:

Retinal vein occlusion Pipeline Insights, DelveInsight

"Retinal vein occlusion Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Retinal vein occlusion market. A detailed picture of the Retinal vein occlusion pipeline landscape is provided, which includes the disease overview and Retinal vein occlusion treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinal-vein-occlusion-market-analysis-epidemiology-insights-therapies-companies-by-delveinsight-abbvie-roche-regeneron-pharmaceuticals-taiwan-liposome-company-aerie-pharmaceuticals-graybug]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.